Stada And Xbrane Win EU Endorsement For Ranibizumab

Ximluci, Third Biosimilar Rival To Lucentis, Receives Positive Opinion From CHMP

 
• By Dave Wallace

Stada and Xbrane have celebrated an endorsement from the EMA’s CHMP for their Ximluci ranibizumab biosimilar rival to Lucentis. The development follows a setback for a parallel filing in the US.

EU flag reflected in eye
Stada and Xbrane are eyeing the third European biosimilar ranibizumab approval • Source: Shutterstock

More from Biosimilars

More from Products